The Victory Sophus Emerging Markets Fund outperformed its benchmark in Q4 2024 despite global volatility. Read the full ...
Background Secondary prevention is critical for patients with established atherosclerotic cardiovascular diseases (ASCVD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results